Sunlenca 464 mg solution for injection clinical trials

(CAbotégravir LENacapavir DUal Long Acting). Phase II, Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA

This study is looking at two long-acting HIV medicines given together to see how well they control the virus. It's for adults living with HIV and aims to find out if this combination is effective and safe over 48 weeks.